Uncategorized

Pharmazac launched the first Rosuvastatin generic in the Greek Pharmaceutical Market. Rosuvastatin is available in two forms of 14 and 30 film coated tablets and composition of […]

  Pharmazac a Member of the Hellenic Association of Pharmaceutical Companies,  announces the completion of the successful Conference of the Hellenic Society of Headache,  that took place  […]

Pharmazac launched the new product Quental/quetiapine 50,200,300 and 400mg in prolonged release tablets for the treatment of schizophrenia and bipolar disorders.

Pharmazac launched Etrozac / etoricoxib a selective cyclo-oxygenase – 2 (COX-2) inhibitor. Etrozac indicated for the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain and […]

Pharmazac has developed in its laboratories and launched in the Greek pharmaceutical market a nutraceutical, the titrate extract of Petasitis Hybridus in liquid hard gelatin capsules […]

Pharmazac participates in CPhI 2018.

Pharmazac launched the new product Abelfiz / aripiprazole 10, 15 and 30mg in hard tablets  for the treatment of schizophrenia in adults and in adolescents aged […]

Pharmazac launched the new product  Vasitimb / ezetimibe + simvastatin for theprevention of cardiovascular events, for hypercholesterlaemia and for theHomozygous Familial Hypercholesterolaemia. Therapeutic Indications Prevention of Cardiovascular Events Vasitimb is […]